Eurazeo Invests in Cancer-Fighting Radioisotope Production
Company Announcements

Eurazeo Invests in Cancer-Fighting Radioisotope Production

Eurazeo (FR:RF) has released an update.

Eurazeo, in partnership with Kurma Partners, has invested in PanTera through a €93 million financing round aimed at establishing large-scale production of Actinium-225, a promising cancer-fighting radioisotope. This investment marks Eurazeo’s second Growth Equity investment and reinforces its commitment to healthcare innovation in Europe. PanTera plans to significantly increase production to support 100,000 patients annually by 2029, contributing to European medical sovereignty and access to healthcare.

For further insights into FR:RF stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks European Auto-Generated NewsdeskEurazeo Announces Share Capital and Voting Rights
TipRanks European Auto-Generated NewsdeskKurma Partners Launches EUR 250 Million Biofund IV
TipRanks European Auto-Generated NewsdeskEurazeo’s Grape Hospitality Sells 22 French Hotels
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App